Second-line adult HIV/AIDS project
Description of the project
Increasing access and reducing prices through market expansion
Since the 2007 launch of the Second-line adult HIV/AIDS project, CHAI has worked diligently to expand access to second-line adult HIV treatment and has had a tremendous impact on market dynamics and patient outcomes through its partnership with UNITAID, reaching over 110 000 patients and reducing prices on leading second-line antiretroviral (ARV) regimens by over 70%, reducing the price of second-line treatment from US$ 1500 per patient per year in 2006 to an average of US$ 450 in 2011.
When the project started, it supported the 26 beneficiary countries: Benin, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon, Chad, Côte d'Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, Haiti, India, Kenya, Malawi, Mali, Mozambique, Namibia, Nigeria, Rwanda, Senegal, Togo, Uganda, United Republic of Tanzania, Zambia, and Zimbabwe. Sixteen countries had transitioned to alternative funding sources by the end of 2011. The remaining 10 countries all have plans in place to transition out of the project during 2012: Burundi, Cameroon, Democratic Republic of Congo, Haiti, India, Mozambique, Nigeria, Uganda, Zambia, and Zimbabwe.
HIV is a life-long, chronic disease, and people receiving antiretroviral treatment (ART) need access to newer and more potent HIV drugs if they become resistant to their initial set of drugs or if they develop serious side-effects to their existing drugs. However, these newer medicines are significantly more expensive than first-line HIV medicines. At the same time, the need for these newer medicines is increasing at a rapid pace.
| A. | Project title: | Second-line adult HIV/AIDS project |
| B. | Timeframe: | Project duration: 2007–2011 |
| C. | Amount committed by UNITAID: | US$ 305 799 000 |
| D. | Lead partner: | Clinton Health Access Initiative (CHAI) |
| E. | Other partner(s): |
